Yazar "Sakalar, T." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey
    (Elsevier Science Inc, 2018) Kilickap, S.; Ozturk, A.; Karadurmus, N.; Korkmaz, T.; Yumuk, P.; Cicin, I.; Paydas, S.; Cilbir, E.; Sakalar, T.; Uysal, M.; Uskent, N.; Demir, N.; Sakin, A.; Turhal, N.; Keskin, S.; Tural, D.; Eralp, Y.; Basal, F.; Yasar, H.; Sendur, M. A.; Demirci, U.; Cubukcu, E.; Karaagac, M.; Karaca, S.; Tatli, A.; Yetisyigit, T.; Urvay, S.; Gursoy, P.; Uluc, B. Oyan; Turna, Z.; Kucukoner, M.; Olmez, O.; Cabuk, D.; Seker, M.; Unal, O.; Meydan, N.; Okutur, S.; Tunali, D.
  • Küçük Resim Yok
    Öğe
    The efficacy and safety analysis of the treatments of everolimus and exemestane combination in 101 metastatic breast cancer patients: Real-life experience from Turkey
    (Amer Assoc Cancer Research, 2019) Bilici, A.; Menekse, S.; Akin, S.; Degirmenci, M.; Olmez, O. F.; Avci, N.; Sakalar, T.; Tural, D.; Kaplan, M. A.; Tanriverdi, O.; Bilgetekin, I.; Uslu, R.
  • Küçük Resim Yok
    Öğe
    PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study
    (Elsevier Ltd, 2023) Avcı, O.; Iriagaç, Y.; Çavdar, E.; Karaboyun, K.; Araz, M.; Sakalar, T.; Değerli, E.
    Introduction: In this study, the toxicities and management of palbociclib and ribociclib in older patients (?65 years) with metastatic breast cancer patients were investigated. Materials and Methods: Among older patients receiving palbociclib and ribociclib, Geriatric 8 (G8) and Groningen Frailty Index were used to evaluate frailty status. Dose modifications, drug withdrawal and other serious adverse events (SAEs) were recorded and analyzed according to baseline patient characteristics. Results: A total of 160 patients from 28 centers in Turkey were included (palbociclib = 76, ribociclib = 84). Forty-three patients were ? 75 years of age. The most common cause of first dose modification was neutropenia for both drugs (97% palbociclib, 69% ribociclib). Liver function tests elevation (10%) and renal function impairment (6%) were also causes for ribociclib dose modification. Drug withdrawal rate was 3.9% for palbociclib and 6% for ribociclib. SAEs were seen in 11.8% of those taking palbociclib and 15.5% of those on riboclib. An ECOG performance status of ?2 and being older than 75 years were associated with dose reductions. Severe neutropenia was more common in patients with non-bone-only metastatic disease, those receiving treatment third-line therapy or higher, coexistance of non-neutropenic hematological side effects (for ribociclib). Neutropenia was less common among patients with obesity. Discussion: Our results show that it can be reasonable to start palbociclib and ribociclib at reduced dose in patients aged ?75 years and/or with an ECOG performance status ?2. © 2023 Elsevier Ltd